Physicochemical characterization of Novel Particulate Delivery Systems for Antitumor/metastatic Therapeutics

Author:

Samuel Girgis1,Nazim Uddin1,Srag El-Din Ahmed S. G.2

Affiliation:

1. Department of Pharmaceutical Science, School of Pharmacy, University of Sunderland, England.

2. Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Egypt.

Abstract

The main objective of this project was to overcome the drawbacks of the emulsification techniques during rising a delivery system for a novel and potent anticancer drug, CK-10, projected for enlightening the therapeutic index of the drug. Emulsion/Solvent evaporation and innovative microfluidic techniques were used to frame the nanoparticles. Loading efficiency and in-vitro release were characterized by a modified Lowry assay. Size and zeta potential were analyzed by dynamic light scattering, laser obscuration time, and tuneable pore resistive sensing. Compatibility and shelf life were tested by differential scanning calorimeter and Fourier transform infra-red. The extent of the nanoparticles degradation was measured by color indicator and potentiometric titrations. The result showed that PLGA/B Cyclodextrin nanoparticles had a higher peptide loading efficiency by 53.92% for the novel microfluidic technique as well as higher in-vitro release and better degradation. PLGA/B Cyclodextrin and PLGA/HPMA nanoparticles had a closely related size and zeta potential. It was concluded that the novel microfluidic technique could augment the physicochemical properties of the CK-10 nanoparticles to improve its pharmacokinetics and pharmacodynamics.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference40 articles.

1. Hajare, R.; Parwani, K.; Bajad, S.; Chandekar, N.; Chandewar, A., Breast Cancer and Indole-3-Carbinol: Controversy of Estrogen Level and Enzyme Elastase. Research Journal of Pharmacy and Technology. 2009, 2, 439-440.

2. Bhasker, S.; Sandeep, G.; Ranganath, Y., Future of Cancer Therapy-COX-2 Inhibitors: A Review. Research Journal of Pharmacy and Technology. 2009, 2, 617-620.

3. Rush, M. G.; Drivas, G.; D'eustachio, P., The small nuclear GTPase Ran: how much does it run? Bioassays 1996, 18, 103-112.

4. Sazer, S., The search for the primary function of the Ran GTPase continues. Trends in Cell Biology. 1996, 6, 81-85.

5. Scheffzek, K.; Klebe, C.; Fritz-Wolf, K.; Kabsch, W.; Wittinghofer, A., Crystal structure of the nuclear Ras-related protein Ran in its GDP-bound form. Nature. 1995, 374, 378-381.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Scaling up and evaluation of Dyphylline controlled release matrix tablets;Research Journal of Pharmacy and Technology;2023-11-30

2. Preparation and in-vitro evaluation of dyphylline controlled release matrix tablets;Research Journal of Pharmacy and Technology;2023-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3